Expertise in
25
conditions

Dr. Teresa C. Gentile

Hematology
Office
750 E Adams St, 
Syracuse, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
25
conditions
Office
750 E Adams St, 
Syracuse, NY 

Overview

Teresa Gentile is a Hematologist practicing medicine in Syracuse, New York.

Dr. Gentile is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Hospital Affiliations

University Hospital S U N Y Health Science Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Office
750 E Adams St, Syracuse, NY 13210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of Therapy
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Carfilzomib, Daratumumab, Dexamethasone, Selinexor
Study Phase: Phase 2
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Unknown
Publish Date: July 01, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: June 15, 2022
Intervention Type: Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Pomalidomide
Study Phase: Phase 2
View 7 Less Clinical Trials

21 Total Publications

Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study.
Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study.
Journal: Hematological oncology
Published: June 04, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Cayuga Medical Center At Ithaca

101 Dates Dr, 
Ithaca, NY 
 (44.4 miles away)
607-272-5414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Mato is a Hematologist practicing medicine in Ithaca, New York. Dr. Mato is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
46
conditions
Expertise in
46
conditions
Referral may be required

Office

5008 Brittonfield Pkwy, 
East Syracuse, NY 
 (6.0 miles away)
315-472-7504
Languages Spoken:
English
See accepted insurances

Tarek Sousou is a Hematologist practicing medicine in East Syracuse, New York. Dr. Sousou is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, and Bone Marrow Aspiration.

Expertise in
41
conditions
Expertise in
41
conditions
Referral may be required

Community General Hospital

4900 Broad Rd, 
Syracuse, NY 
 (2.7 miles away)
315-472-7504
Languages Spoken:
English
See accepted insurances

Benny Yiu Wong is a Hematologist practicing medicine in Syracuse, New York. Dr. Yiu Wong is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Anemia, Thrombocytopenia, Leukocytosis, Essential Thrombocythemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Teresa C. Gentile

How do I make an appointment with Dr. Teresa C. Gentile?

You can book an appointment with Dr. Teresa C. Gentile by calling their office at 315-464-8200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Teresa C. Gentile a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Teresa C. Gentile is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Teresa C. Gentile specialize in?

While Dr. Teresa C. Gentile is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Multiple Myeloma, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Teresa C. Gentile participate in research or clinical trials?

Yes. Dr. Teresa C. Gentile has published 21 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Teresa C. Gentile's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Teresa C. Gentile accept my insurance?

Dr. Teresa C. Gentile accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 315-464-8200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gentile's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile